Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III...
Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing c...
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
CHU de Saint-Etienne, Saint-Etienne, France
St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
Ghent University Hospital, Ghent, Belgium
Jewish General Hospital, Montreal, Quebec, Canada
Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
Consultant phD professor Anne-Mette Hvas, Aarhus, Central Denmark Region, Denmark
Department of Obstetrics, Randers, Denmark
Security Forces Hospital, Riyadh, Saudi Arabia
Cornell Weill Scholl of Medicine, New York, New York, United States
University of Southern California, Los Angeles, California, United States
Ottawa Health Research Institute, Ottawa, Ontario, Canada
Calgary Health Region, Calgary, Alberta, Canada
Pneumology Service. Hospital do Meixoeiro, Vigo, Pontevedra, Spain
Pneumology Service. Hospital Clínico, Santiago de Compostela, A Coruña, Spain
Pneumology Service. Hospital Xeral Cies, Vigo, Pontevedra, Spain
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.